|
nasdaq:nstg
|
75835
|
Apr 21st, 2024 12:00AM
|
NanoString Technologies, Inc.
|
52K
|
613.00
|
Open
|
|
Apr 20th, 2024 11:51PM
|
Apr 20th, 2024 11:51PM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 20th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
52K
|
613.00
|
Open
|
|
Apr 19th, 2024 11:49PM
|
Apr 20th, 2024 05:23PM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 19th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
52K
|
611.00
|
Open
|
|
Apr 18th, 2024 11:56PM
|
Apr 18th, 2024 11:56PM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 18th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
52K
|
611.00
|
Open
|
|
Apr 18th, 2024 12:04AM
|
Apr 18th, 2024 06:44PM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 17th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
51K
|
610.00
|
Open
|
|
Apr 16th, 2024 11:47PM
|
Apr 17th, 2024 03:10PM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 16th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
51K
|
609.00
|
Open
|
|
Apr 15th, 2024 11:43PM
|
Apr 16th, 2024 11:26AM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 15th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
51K
|
609.00
|
Open
|
|
Apr 14th, 2024 11:38PM
|
Apr 15th, 2024 05:07PM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 14th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
51K
|
610.00
|
Open
|
|
Apr 13th, 2024 11:27PM
|
Apr 13th, 2024 11:27PM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 13th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
51K
|
609.00
|
Open
|
|
Apr 12th, 2024 11:18PM
|
Apr 13th, 2024 11:52AM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:nstg
|
75835
|
Apr 12th, 2024 12:00AM
|
NanoString Technologies, Inc.
|
51K
|
610.00
|
Open
|
|
Apr 11th, 2024 11:24PM
|
Apr 12th, 2024 08:47AM
|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.
|
Open
|
Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research
|
Open
|
530 Fairview Avenue N
|
Seattle
|
WA
|
US
|
98109
|
|
NanoString Technologies
|
Health Care
|
Pharmaceuticals & Biotechnology
|